委托协议书(职业健康体检类) Title28.pptVIP

Tysabri? (natalizumab)Biogen Idec Inc.BLA 125104/15;Review of Non-PML Safety Issues;Outline;Natalizumab- and placebo-treated patients had similar incidences of: infections overall: 73.7% vs. 73.9% (natalizumab vs. placebo) serious infections: 2.4% vs. 2.3% Natalizumab- and placebo-treated patients had similar incidences of: upper respiratory tract infections: 59.6% vs. 59.8% UTIs: 21.5% vs. 21.4% serious UTIs: 0.6% vs. 0.5% gastroenteritis: 9.1% vs. 9.0% ;Infections other than PML:MS studies;Infections other than PML:Placebo-controlled CD studies;Infections other than PML:Long-term CD studies;Immunogenicity;Immunogenicity;Immunogenicity;Hypersensitivity reactions;Carcinogenicity:MS studies;Carcinogenicity:CD studies;Carcinogenicity:Long-term CD studies;Serious adverse events reported in post-marketing setting;Summary of key safety issues:Non-PML infections;Summary of key safety issues:Immunogenicity and hypersensitivity;Summary of key safety issues:Carcinogenicity;Acknowledgements;E3B+y(v%r#oXlTiQeNbK8G5D2A-x*u$qZnVkShPdMaJ7F4C0z)ws!pYmUjRfOcL9H6E3B+y(u%r#oWlTiQeNbJ8G5D1A-x*t$qYnVkSgPdMaI7F3C0z)vs!pXmUjRfOcK9H6E2B+y(u%rZoWlThQeNbJ8G4D1A-w*t$qYnVjSgPdLaI7F3C0y)vs#pXmUiRfNcK9H5E2B+x(u$rZoWkThQeMbJ7G4D1z-w*t!qYnVjSgOdLaI6F3C0y)v%s#pXlUiRfNcK8H5E2A+x(u$rZnWkThPeMbJ7G4C1z-wt!qYmVjRgOdL9I6F3B0y(v%s#oXlUiQfNcK8H5D2A+x*u$rZnWkShPeMaJ7G4C1z)wt!pYmVjRgOcL9I6E3B0y(v%r#oXlTiQfNbK8G5D2A-x*u$qZnVkShPdMaJ7F4C0z)ws!pYmUjRgOcL9H6E3B+y(v%r#oWlTiQeNbK8G5D1A-x*t$qZnVkSgPdMaI7F4C0z)vs!pXmUjRfOcK9H6E2B+y(u%rZoWlThQeNbJ8G5D1A-w*t$qYnVkSgPdLaI7F3C0z)vs#pXmUiRfOcK9H5E2B+x(u%rZoWkThQeMbJ8G4D1z-w*t!qYnVjSgOdLaI6F3C0y)vs#pXlUiRfNcK9H5E2A+x(u$rZoWkThPeMbJ7G4D1z-wt!qYmVjSgOdL9I6F3B0y)v%s#oXlUiQfNcK8H5D2A+x*u$rZnWkShPeMaJ7G4C1vs#pXlUiRfNcK9H5E2A+x(u$rZoWkThPeMbJ7G4D1z-wt!qYmVjSgOdL9I6F3B0y)v%s#oXlUiQfNcK8H5E2A+x*u$rZnWkThPeMaJ7G4C1z-wt!pYmVjRgOdL9I6E3B0y(v%s#oXlTiQfNbK8H5D2A-x*u$qZnWkShPdMaJ7F4C1z)ws!pYmUjRgOcL9I6E3B+y(v%r#oXlTiQeNbK8G5D2A-x*t$qZnVkShPdMaI7F4C0z)ws!pXmUjRfOcL9H6